You zero in on exactly what is so great about K: multiple trials will be ongoing for multiple indications in the next months. For retinoblastoma, I'll take a PH2/3 combo with breakthrough designation. For solid tumors it is likely that differing "types" will be mapped according to their response shown in the pk/pd/scan data now being collected at DF/BI, and Shapiro will want to follow with a specific Ph2 & 3. Results from data will dictate next phases in any case.